The Positron Emission Tomography Ligand DAA1106 Binds With High Affinity to Activated Microglia in Human Neurological Disorders
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Chronic microglial activation is an important component of many neurological disorders, and imaging activated microglia in vivo will enable the detection and improved treatment of neuroinflammation. 1-(2-chlorphenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline-carbox-amide (PK11195), a peripheral benzodiazepine receptor ligand, has been used to image neuroinflammation, but the extent to which PK11195 binding distinguishes activated microglia and reactive astrocytes is unclear. Moreover, PK11195 may lack sufficient sensitivity for detecting mild neuroinflammation. We hypothesized that N-(2,5-dimethoxybenzyl)-N-(4-fluoro-2-phenoxyphenyl) acetamide (DAA1106), a new ligand that binds specifically to peripheral benzodiazepine receptor, binds to activated microglia in human neurological diseases with higher affinity than does PK11195. We therefore compared the pharmacological binding properties of [3H](R)-PK11195 and [3H]DAA1106 in postmortem tissues from patients with cerebral infarcts, amyotrophic lateral sclerosis, Alzheimer disease, frontotemporal dementia, and multiple sclerosis (n=10 each). In all diseases, [3H]DAA1106 showed a higher binding affinity as reflected by lower dissociation constant (KD) values than that of [3H](R)-PK11195. Moreover, specific binding of both ligands correlated with the presence of activated microglia identified by immunohistochemistry in situ. We conclude that 1) ligands that bind peripheral benzodiazepine receptor mainly label activated microglia in human neurological disorders and that 2) DAA1106 may possess binding characteristics superior to those of PK11195, which may be beneficial for in vivo positron emission tomography imaging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 2×
“Microglia undergo activation in response to neuronal injury, but when they are chronically activated, they are also sources of neurotoxins that may enhance neuronal and synaptic damage (1).”
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 1×
“[(11)C](R)-PK11195 shows increased brain retention in the comparison of control human subjects to varying extents with patients with Alzheimer disease (AD) (3); amyotrophic lateral sclerosis (ALS) (4); multiple sclerosis (MS) (5Y7); Parkinson disease (8, 9); frontotemporal dementia (FTD) (10); corticobasal degeneratio…”
In-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 1×
“[(11)C](R)-PK11195 shows increased brain retention in the comparison of control human subjects to varying extents with patients with Alzheimer disease (AD) (3); amyotrophic lateral sclerosis (ALS) (4); multiple sclerosis (MS) (5Y7); Parkinson disease (8, 9); frontotemporal dementia (FTD) (10); corticobasal degeneratio…”
Turner, M. R., Cagnin, A., Turkheimer, F. E., Miller, C. C. J., Shaw, C. E., Brooks, D. J., Leigh, P. N., & Banati, R. B. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.012 · Cited by 737 · cited 7×
“The extent of microglial activation and of reactive astrocytosis was assessed in postmortem brain tissues from patients with cerebrovascular infarcts, MS, FTD, ALS, and AD (n = 10 each condition) and compared with controls (n = 6).”
InfluentialMicroglial activation correlates with severity in Huntington disease: A clinical and PET study
Pavese, N., Gerhard, A., Tai, Y. F., Ho, A. K., Turkheimer, F., Barker, R. A., Brooks, D. J., & Piccini, P. (2006) · Neurology · doi:10.1212/01.wnl.0000222734.56412.17 · Cited by 462 · cited 1×
“[(11)C](R)-PK11195 shows increased brain retention in the comparison of control human subjects to varying extents with patients with Alzheimer disease (AD) (3); amyotrophic lateral sclerosis (ALS) (4); multiple sclerosis (MS) (5Y7); Parkinson disease (8, 9); frontotemporal dementia (FTD) (10); corticobasal degeneratio…”
Microglial activation in presymptomatic Huntington's disease gene carriers
Tai, Y. F., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., & Piccini, P. (2007) · Brain · doi:10.1093/brain/awm044 · Cited by 440
Visualising microglial activation in vivo
Banati, R. B. (2002) · Glia · doi:10.1002/glia.10144 · Cited by 428
Venneti, S., Lopresti, B. J., & Wiley, C. A. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.10.002 · Cited by 373
Self-citationConde, J. R., & Streit, W. J. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000202887.22082.63 · Cited by 344
Banati, R. B., Goerres, G. W., Myers, R., Gunn, R. N., Turkheimer, F. E., Kreutzberg, G. W., Brooks, D. J., Jones, T., & Duncan, J. S. (1999) · Neurology · doi:10.1212/wnl.53.9.2199 · Cited by 224
Cited by
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Microglia: biology and pathology
Graeber, M. B., & Streit, W. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0622-0 · Cited by 725
Roles of microglia in brain development, tissue maintenance and repair
Michell-Robinson, M. A., Touil, H., Healy, L. M., Owen, D. R., Durafourt, B. A., Bar-Or, A., Antel, J. P., & Moore, C. S. (2015) · Brain · doi:10.1093/brain/awv066 · Cited by 425
Astrocyte Regulation of Blood Flow in the Brain
MacVicar, B. A., & Newman, E. A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020388 · Cited by 420
In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease
Kreisl, W. C., Lyoo, C. H., McGwier, M., Snow, J., Jenko, K. J., Kimura, N., Corona, W., Morse, C. L., Zoghbi, S. S., Pike, V. W., et al. (2013) · Brain · doi:10.1093/brain/awt145 · Cited by 350
“However, results from transgenic mouse and autopsy studies have shown that increased TSPO density in Alzheimer’s disease brain co-localizes to microglia rather than astrocytes (Venneti et al ., 2008; Gulyas et al ., 2009).”
Background
Metadata
- Authors
- Venneti, S., Wang, G., Nguyen, J., & Wiley, C. A.
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-10
- Volume
- 67
- Issue
- 10
- Pages
- 1001-1010
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- OpenAlex
- W2059098049
- Cited by
- 118
- References
- 13
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Positron Emission Tomography Ligand DAA1106 Binds With High Affinity to Activated Microglia in Human Neurological Disorders. https://app.cochat.ai/papers/10.1097/nen.0b013e318188b204
- The paper
- Venneti, S., Wang, G., Nguyen, J., & Wiley, C. A. (2008). The Positron Emission Tomography Ligand DAA1106 Binds With High Affinity to Activated Microglia in Human Neurological Disorders. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1097/nen.0b013e318188b204
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.